The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer
Companies Mentioned Include:
- AbbVie Inc
- Acetylon Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Limited
- EirGenix Inc.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Esperance Pharmaceuticals, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Lee's Pharmaceutical Holdings Limited
- Mabion SA
- MabVax Therapeutics Holdings, Inc.
- Mateon Therapeutics Inc
- MedImmune, LLC
- Vascular Biogenics Ltd.
- VentiRx Pharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/74pzhx/peritoneal_cancer